CYTEK
TRANSCEND THE CONVENTIONAL

Q2 2026 Earnings Presentation

August 5, 2026

Safe Harbor Statement

This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's future financial performance, including its outlook and expected revenue for the year ended December 31, 2026; Cytek's growth and business strategies, product plans and expectations, market trends and opportunities, and any expectations or assumptions thereto; Cytek's ability to effectively navigate uncertain times and strengthen its competitive position as a market leader; Cytek's ability to successfully implement its operational plans and business strategies, including, but not limited to, its plans to create new business units and its ability to expand its global installed base and grow its recurring revenue streams; Cytek's potential for sustainable growth and profitability; and any statements regarding current or future macroeconomic trends or events and the impact of those trends and events on Cytek and its financial performance. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or the negatives of these terms or variation of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, without limitation, global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. Information on these and additional risks and uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission (the "SEC") on May 7, 2026, and Cytek's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, to be filed with the SEC on or about the date hereof, and other filings Cytek makes with the SEC from time to time. Unless otherwise indicated, these forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

This presentation and the related conference call and webcast include certain financial information in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") and also on a non-GAAP basis for the three-month period ended June 30, 2026 and June 30, 2025. Management believes that non-GAAP financial measures, including "Adjusted gross profit," "Adjusted gross margin," "Adjusted EBITDA," and "Adjusted EBITDA excluding investment income," taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company's core operating results. Management uses non-GAAP measures to compare the company's performance relative to forecasts and strategic plans and to benchmark the company's performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the tables accompanying this presentation.

Q2 2026 Revenue Results[1]



1. As of quarter ended 6/30/2026. $ Millions

Q2 2026 Commentary

Continued positive momentum through the second quarter, delivering another period of solid revenue growth

Q2 2026 Revenue grew 6% Y/Y driven by:

- Strong double-digit revenue growth in the U.S. and in China
- Mid-teens growth from FSP instruments
- Consistent double-digit growth in service business

Revenue by Geographic Region[1]



Q2 2026 Commentary

US: Revenue was up 18% Y/Y driven by impressive growth in instruments in academic and government and services

EMEA: Revenue was down 8% Y/Y due to continued budgetary pressures from regional geopolitical dynamics

APAC: Revenue was flat Y/Y with China delivering strong double-digit growth offset by softness elsewhere in the region

1. EMEA = Europe, Middle East, & Africa; APAC = Asia-Pacific. $ Millions

Q2 Business Highlights[1]

Expanded to a total installed base of 3,933 Cytek instruments, adding 142 units in Q2

Solid instrument unit growth in Q2 driven by high-end instruments, which increased by 11% Y/Y

Grew Cytek Cloud to over 28K users in Q2 2026, up 15% since the start of the year

Launched Cytek Borealis, a new 7-laser full spectrum flow cytometer with proprietary matching reagents to enable high-resolution 60-color panel

Introduced new Cytek Aurora Evo instrument configurations with expanded automation capabilities for highly automated lab environments

Recurring revenue was $18.5 million, up 8% Y/Y, representing 35% of Cytek revenue over TTM, up from 32% from a year ago

1. Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Recurring revenue is comprised of service and reagent revenue; TTM = trailing-twelve-months.

Extending our Leadership in the Spectral Flow Cytometry Market

INTRODUCING THE NEW

Cytek Borealis™ Flow Cytometer

Revolutionary, next-generation flow cytometry

- First-ever 60 color, 7-laser Flow Cytometer with proprietary matching reagents
- Accommodates nanoparticle sizes enabling a high diversity of sample types
- Chassis design accommodates future integrated cell imaging via upgrade
- High flowrates increases the speed of analysis and throughput of the system
- Enhanced automation eliminates the need for manual sample handling

Unparalleled analytical breadth expands the possibilities of cellular discovery

CYTEK TRANSCEND THE CONVENTIONAL

Strengthening our Market Leadership

INTRODUCING THE NEW

Cytek Aurora™ Evo

with enhanced automation capabilities

- Full-spectrum 40+ color, 5-laser Flow Cytometry
- Expanded automation capabilities for highly-automated laboratory environments
- Automated and remote start-up, shut-down, door operation, monitoring and temperature control
- API to interface with automated plate handling systems, eliminates the need for human intervention

Enabling full integration into highly automated lab environments

Revenue Mix

By Region



18% Y/Y US Growth

Product & Service



10% Y/Y Service Growth

In $ Millions

Q2 2026 Financial Overview

$ in millions	Q2 2025	Q2 2026	Y/Y
Total Revenue	$45.6	$48.1	6%
Gross Profit	$23.9	$28.3	19%
Gross Margin	52%	59%	NM
Operating Expenses:			
Research and Development	$8.8	$9.7	10%
Sales and Marketing	$12.1	$13.2	9%
General and Administrative[1]	$13.5	$16.8	24%
Total Operating Expenses	$34.5	$39.7	15%
Loss from Operations	$(10.6)	$(11.4)	NM
Net Loss	**$(5.6)**	**$(12.2)**	**NM**
Non-GAAP Adjusted EBITDA[2]	**$1.3**	**$(1.5)**	**NM**

1. Year-over-year increase in General and Administrative expenses were due primarily to previously disclosed litigation-related expenses, severance, and personnel costs.
2. See Appendix for reconciliation of GAAP to non-GAAP figures

CYTEK TRANSCEND THE CONVENTIONAL

Updated 2026 revenue guidance, increasing by $1M at the midpoint

FY 2026 Revenue Guidance[1]

$207 - $212

million

+3 to +5% Y/Y growth

1. Assumes no change from current currency exchange rates

2026 Strategic Priorities

Global Diversification

Accelerate **market penetration of instruments** across multiple geographies

Technology Platform Leader

Advance technological leadership with continuous **innovation**

Growing Recurring Revenue

Drive **reagent and service businesses** benefitting from established and **expanding global installed base**

Attractive Financial Profile

Well-positioned to deliver long-term profitable, sustainable growth through differentiated technology portfolio, durable growth drivers, strong balance sheet, and global reach

Appendix

Creating New Business Units to Drive Growth

Aligns sales, marketing and R&D resources on distinct customer needs to accelerate Cytek's growth

1 Research Technology Business Unit

- High-end instruments to research use only customers
- ✓ Robust replacement cycle for high-end instruments
- ✓ Continuous innovation with state-of-the art instruments

2 Solutions and Clinical Business Unit

- Low/mid-range instruments and reagents to solutions-oriented customers
- ✓ Largely unexploited opportunity in QA/QC
- ✓ >$150M reagents flow across our installed base
- ✓ Low current share = big growth opportunity

3 Service Business Unit

- System maintenance and repair services for other Business Units
- ✓ Revenue grows with installed base growth

— To Be Completed in Q3 2026 —

CYTEK
TRANSCEND THE CONVENTIONAL

Reconciliation of GAAP to Non-GAAP Measures (Unaudited)

	Three Months Ended		Six Months Ended	
(In thousands)	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
GAAP gross profit	$ 28,340	$ 23,867	$ 49,594	$ 44,024
Stock based compensation	$ 736	$ 1,110	$ 1,465	$ 2,196
Amortization of acquisition-related intangible assets	$ 490	$ 481	$ 984	$ 974
Non-GAAP adjusted gross profit	**$ 29,566**	**$ 25,458**	**$ 52,043**	**$ 47,194**
GAAP gross margin	59 %	52 %	54 %	51 %
Non-GAAP adjusted gross margin	61 %	56 %	56 %	54 %
GAAP net income	**$ (12,158)**	**$ (5,583)**	**$ (31,024)**	**$ (16,985)**
Depreciation and amortization	$ 2,985	$ 2,988	$ 5,797	$ 5,869
Provision for (benefit from) income taxes	$ 515	$ (1,192)	$ 2,008	$ (1,056)
Interest income	$ (819)	$ (555)	$ (1,606)	$ (1,062)
Interest expense	$ 281	$ 414	$ 543	$ 705
Foreign currency exchange loss (gain)	$ 729	$ (1,593)	$ 1,881	$ (2,871)
Stock based compensation	$ 5,339	$ 6,791	$ 10,200	$ 13,420
Write-off Investment	$ 1,587	$ —	$ 1,587	$ —
Non-GAAP adjusted EBITDA	**$ (1,541)**	**$ 1,270**	**$ (10,614)**	**$ (1,980)**
Investment income	$ (1,383)	$ (2,048)	$ (3,012)	$ (4,309)
Non-GAAP adjusted EBITDA excluding investment income	**$ (2,924)**	**$ (778)**	**$ (13,626)**	**$ (6,289)**

CYTEK
TRANSCEND THE CONVENTIONAL

Thank You